Fig. 1: Distinct expansion pattern of of cilta-cel vs. ide-cel CAR-T in myeloma patients in the real-world setting.

Time course of CAR T cell numbers expressed as T cells identified by surface expression of the CAR using CAR detection reagent and flow cytometry for (A) total CAR T, (B) CD4⁺ CAR T, (C) CD8⁺ CAR T, and (D) CD4⁺CD8⁺ CAR T and proportions in myeloma patients after lymphodepleting chemotherapy and CAR T cell infusion. Data are expressed as the respective CAR-T subtype per total number of T cells. Blue curves indicate cilta-cell numbers and red curves indicate ide-cell numbers. E Levels of CD4⁺ and CD8⁺ Non-CAR T cells in the patients’ blood at the time of apheresis for cilta-cel (blue; N = 15) vs. ide-cel (red; N = 11) patients. F Peak CD3⁺ CAR T levels, peak CD4⁺ CAR T levels, peak CD8⁺ CAR T levels, peak CD4⁺CD8⁺ CAR T levels, time to peak for CD3⁺ CAR T, time to peak for CD4⁺, and time to peak for CD8⁺CAR T for cilta-cel (blue; N = 23) vs. ide-cel (red; N = 16). G CAR T cell numbers at different timepoints post cell infusion for cilta-cel (blue) vs. ide-cel (red). H Surface expression levels of the respective BCMA CAR as measured by flow cytometry after staining with BCMA CAR detection reagent. The histogram shows expression levels on CD3⁺ CAR T in two exemplary patients (gray=unstained control, red=patient who received ide-cel, blue=patient who received cilta-cel). The bar graph on the right shows surface expression levels of the given CAR at peak in the two groups of patients (blue, N = 23; red=ide-cel, N = 16). Bar graphs indicate median values with 95% confidence intervals (CI). Statistical differences between groups were calculated using a two-sided Mann-Whitney U test. Source data are provided as a Source Data file.